Medicine guide

Piasky

·

  • Prescription status not stated
  • Cancer treatments and immune-system medicines
Active substance
Crovalimab
Made by
Roche Registration GmbH

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byRoche Registration GmbH
Active substanceCrovalimab
Used inCancer treatments and immune-system medicines
ClassificationL04AJ07 · Cancer treatments and immune-system medicines
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on2024-08-22
Last updated by the regulator2026-05-22
EMA product numberEMEA/H/C/006061

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).